How does the NFL value change longitudinally after a change or start of disease modifying treatment?

How does the NFL value change longitudinally after a change or start of disease modifying treatment? - NFLswtich

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032753

Enrollment

100

Registered

2023-10-06

Start date

2023-10-18

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: People with multiple sclerosis (pwMS) who start a new disease-modifying treatment (DMT) or switching from one to another. We plan to measure serum neurofilament (sNfl) in the setting of rout

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinically-isolated syndrome or multiple sclerosis according to current McDonald criteria.

Exclusion criteria

Exclusion criteria: - Factors that contraindicate follow-up examinations as part of the study, e.g. florid alcohol abuse, - Patient not capable of giving consent

Design outcomes

Primary

Measure	Time frame
How fast drops sNfl after treatment start or switch?	—

Secondary

Measure	Time frame
• Does sNfl drop differently (in speed & extent) depending on efficacy of DMT? • Is the drop or stabilisation of sNfl dependant on disease acitivity? • Can a delayed drop or sustained high levels of sNfl predict disease activity under therapy? • Does a longitudinal course of sNfl predict the need of therapy escalation prior magnetic resonance tomographic or clinical signs of disease activity? • Is baseline sNfl predictive of disease activity under DMT? • May sNfl support therapy decision making?	—

Measure

Time frame

• Does sNfl drop differently (in speed & extent) depending on efficacy of DMT? • Is the drop or stabilisation of sNfl dependant on disease acitivity? • Can a delayed drop or sustained high levels of sNfl predict disease activity under therapy? • Does a longitudinal course of sNfl predict the need of therapy escalation prior magnetic resonance tomographic or clinical signs of disease activity? • Is baseline sNfl predictive of disease activity under DMT? • May sNfl support therapy decision making?

—

Countries

Germany

Contacts

Public ContactStefan Bittner

Klinik und Poliklinik für Neurologie, Universitätsmedizin Mainz

stefan.bittner@unimedizin-mainz.de06131172805

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026